Connect with us

Life Sciences

Red Hat Introduces New Partner Subscriptions to Enable Ecosystem Innovation and Customer Success

Red Hat Partner Subscriptions offer partners extended access to the Red Hat open hybrid cloud portfolio at no cost Red Hat, the world’s leading provider…

Published

on

This article was originally published by AITHORITY
Red Hat Introduces New Partner Subscriptions to Enable Ecosystem Innovation and Customer Success

Red Hat Partner Subscriptions offer partners extended access to the Red Hat open hybrid cloud portfolio at no cost

Red Hat, the world’s leading provider of open source solutions,announced the launch of Red Hat Partner Subscriptions, a no-cost subscription model that allows partners deeper access to the Red Hat open hybrid cloud portfolio. Red Hat Partner Subscriptions offer a simplified path for partners to acquire Red Hat product subscriptions that can be used to develop software solutions and proof-of-concepts, test product offerings, deepen technical skills and more.

Recommended AI News: Mobileum and Digis Squared Announce Partnership to Provide Comprehensive Edge-to-Edge Network Testing and Analytics

“Red Hat Partner Subscriptions have simplified the experience for our team to access Red Hat software and support when building environments for education and client demonstrations, which are critical to the day-to-day success of our technical team in serving clients.”

Red Hat Partner Subscriptions equip partners with Red Hat subscriptions typically worth thousands of dollars to develop and sell solutions based on hardened, enterprise-grade open source software, driving improved operational efficiencies and technical capabilities for customers. Replacing traditional Not-for-Resale subscriptions, Red Hat Partner Subscriptions offer partners more comprehensive access to Red Hat’s industry leading platforms, including Red Hat Enterprise Linux, Red Hat OpenShift and Red Hat Ansible Automation Platform, as well as supported offerings, for a broader range of business and technical use cases.

Recommended AI News: Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts

Key benefits for partners through Red Hat Partner Subscriptions include:

  • Access to hundreds of self-support subscriptions for the Red Hat open hybrid cloud portfolio, with the ability for partners to mix and match product subscriptions.
  • Extended use for single- and multi-user software development, testing, internal training, demonstrations, proofs-of-concept and more.
  • Enabled use for on-premises or in any public cloud.
  • Complimentary Red Hat Standard support for up to five contacts, with the option to upgrade for additional contacts or Red Hat Premium support.
  • Applicable for all generally available Red Hat product versions, variants, package updates and add-ons, as well as public Beta versions.

Red Hat Partner Subscriptions are now available to all Red Hat Ready, Advanced and Premier Business Partners. In addition, Red Hat technology partners that have completed or are in the process of completing product certifications with Red Hat can also utilize Red Hat Partner Subscriptions.

Recommended AI News: Kount, an Equifax Company, Expands International Presence

[To share your insights with us, please write to sghosh@martechseries.com]

The post Red Hat Introduces New Partner Subscriptions to Enable Ecosystem Innovation and Customer Success appeared first on AiThority.

therapeutics

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Markets

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending